Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Publication Type:
Journal Article
Authors:
E J Lawitz;
M S Sulkowski;
Ghalib, R.;
Rodriguez-Torres, M.;
Z M Younossi;
Corregidor, A.;
DeJesus, E.;
Pearlman, B.;
Rabinovitz, M.;
Gitlin, N.;
Lim, J.K.;
Pockros, P.J.;
Scott, J.D.;
Fevery, B.;
Lambrecht, T.;
S Owerkerk-Mahadevan;
Callewaert, K.;
Symonds, W.T.;
Picchio, G.;
Lindsay, K.L.;
Beumont, M.;
Ira M. JacobsonSource:
Lancet, Volume 384, Issue 9956, p.1756-1765 (2014)
Keywords:
analysis,
Baltimore,
Belgium,
blood,
chronic HCV,
Cities,
Fatigue,
Gastroenterology,
Genotype,
genotype 1,
HCV,
Headache,
Health,
hepatitis,
Hepatitis C,
hepatitis C virus,
immunology,
Infection,
Intention,
interferon,
Liver,
Medicine,
methods,
Nausea,
New York,
nonresponder,
Patients,
peginterferon,
pegylated,
pegylated interferon,
Research,
Ribavirin,
Safety,
simeprevir,
sofosbuvir,
Texas,
treatment,
treatment-naive,
Universities
